2020
Survivin expression and impact on head and neck cancer outcomes
Khan SA, Burke M, Zhu F, Yang DH, Dubyk C, Mehra R, Lango MJ, Ridge JA, Sher DJ, Burtness B. Survivin expression and impact on head and neck cancer outcomes. Oral Oncology 2020, 112: 105049. PMID: 33221541, PMCID: PMC10916757, DOI: 10.1016/j.oraloncology.2020.105049.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAged, 80 and overApoptosisCell NucleusCyclin-Dependent Kinase Inhibitor p16CytoplasmDisease-Free SurvivalFemaleHumansMaleMiddle AgedNeoplasm ProteinsPrognosisSex FactorsSquamous Cell Carcinoma of Head and NeckSurvivinTissue Array AnalysisTreatment OutcomeTumor Suppressor Protein p53ConceptsOverall survivalSurvivin expressionTissue microarraySurvivin levelsNeck squamous cell carcinomaTotal compartmentFox Chase Cancer CenterNeck cancer outcomesShorter overall survivalSquamous cell carcinomaHigh survivin expressionGrade of tumorAnti-cancer therapySystemic therapyPatient sexSurvival outcomesCancer CenterCell carcinomaCancer outcomesP16 statusPredictive biomarkersPrimary tumorSurvivin protein expressionTreatment responseN stagePredictive classifier for intensive treatment of head and neck cancer
Zakeri K, Rotolo F, Lacas B, Vitzthum LK, Le Q, Gregoire V, Overgaard J, Hackshaw A, Zackrisson B, Parmar MKB, Burtness BA, Ghi MG, Sanguineti G, O’Sullivan B, Fortpied C, Bourhis J, Shen H, Harris J, Michiels S, Pignon J, Mell LK, Intergroup F. Predictive classifier for intensive treatment of head and neck cancer. Cancer 2020, 126: 5263-5273. PMID: 33017867, DOI: 10.1002/cncr.33212.Peer-Reviewed Original ResearchConceptsOverall survivalIntensive treatmentΩ scoreNeck cancerGood performance statusEffect of chemotherapyOral cavity sitesPerformance statusAdvanced headRandomized trialsControl armHigh riskN categoryPatientsRelative hazardYounger ageEvent riskEvent regressionCancerCancer progressionUnknown statusTreatment effectsChemotherapyScoresTreatment
2015
Human Papillomavirus–Associated Oropharyngeal Cancer: Defining Risk Groups and Clinical Trials
Bhatia A, Burtness B. Human Papillomavirus–Associated Oropharyngeal Cancer: Defining Risk Groups and Clinical Trials. Journal Of Clinical Oncology 2015, 33: 3243-3250. PMID: 26351343, PMCID: PMC5814107, DOI: 10.1200/jco.2015.61.2358.Peer-Reviewed Original ResearchConceptsClinical trialsRisk groupsHuman papillomavirus-associated oropharynx cancerHPV-negative OPCPoor-risk subsetTreatment-related morbidityDe-escalation trialsPrognostic risk groupsClinical trial optionsYounger median ageNew treatment strategiesIdeal patient groupNovel therapeutic targetInvasive surgical techniquesDeintensification trialsTreatment deintensificationOropharynx cancerSmoking exposureMetastatic diseaseModality therapyFavorable prognosisMedian ageBetter prognosisSuperior prognosisIntense therapy
2014
p16 status, pathologic and clinical characteristics, biomolecular signature, and long‐term outcomes in head and neck squamous cell carcinomas of unknown primary
Keller LM, Galloway TJ, Holdbrook T, Ruth K, Yang D, Dubyk C, Flieder D, Lango MN, Mehra R, Burtness B, Ridge JA. p16 status, pathologic and clinical characteristics, biomolecular signature, and long‐term outcomes in head and neck squamous cell carcinomas of unknown primary. Head & Neck 2014, 36: 1677-1684. PMID: 24115269, PMCID: PMC3972378, DOI: 10.1002/hed.23514.Peer-Reviewed Original ResearchConceptsSquamous cell CUPNeck squamous cell carcinomaSquamous cell carcinomaUnknown primaryCell carcinomaTissue microarrayOverall survivalP16 statusHuman papillomavirus (HPV) statusMajority of patientsWorse overall survivalLong-term outcomesHPV associationP16 stainClinical characteristicsClinicopathologic characteristicsPrognostic factorsPrognostic featuresPrognostic implicationsExtracapsular extensionP16 stainingYounger ageCarcinomaP16High grade
2013
Phase III Randomized, Placebo-Controlled Trial of Docetaxel With or Without Gefitinib in Recurrent or Metastatic Head and Neck Cancer: An Eastern Cooperative Oncology Group Trial
Argiris A, Ghebremichael M, Gilbert J, Lee JW, Sachidanandam K, Kolesar JM, Burtness B, Forastiere AA. Phase III Randomized, Placebo-Controlled Trial of Docetaxel With or Without Gefitinib in Recurrent or Metastatic Head and Neck Cancer: An Eastern Cooperative Oncology Group Trial. Journal Of Clinical Oncology 2013, 31: 1405-1414. PMID: 23460714, PMCID: PMC3612594, DOI: 10.1200/jco.2012.45.4272.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Squamous CellDiarrheaDocetaxelDrug Administration ScheduleErbB ReceptorsFatigueFemaleGefitinibGenotypeHead and Neck NeoplasmsHumansKaplan-Meier EstimateLeukopeniaMaleMiddle AgedNeoplasm MetastasisNeoplasm Recurrence, LocalProto-Oncogene ProteinsProto-Oncogene Proteins c-metProto-Oncogene Proteins p21(ras)QuinazolinesRas ProteinsTaxoidsTreatment OutcomeConceptsAddition of gefitinibPerformance statusArm ADisease progressionEastern Cooperative Oncology Group performance statusEastern Cooperative Oncology Group trialEpidermal growth factor receptor tyrosine kinase inhibitorsGrowth factor receptor tyrosine kinase inhibitorsReceptor tyrosine kinase inhibitorsGrade 3/4 diarrheaPhase III randomizedSingle-agent gefitinibTrials of docetaxelUnplanned subset analysisECOG performance statusGrade 3/4 toxicitiesMedian overall survivalTime of progressionSquamous cell carcinomaTyrosine kinase inhibitorsEligible patientsMetastatic SCCHNWeekly docetaxelMetastatic headOverall survival